|
|
|
|
| LEADER |
01538nam a2200289 u 4500 |
| 001 |
EB001839973 |
| 003 |
EBX01000000000000001003962 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Neuromuscular monitoring for patients receiving continuous paralytic or neuromuscular blocking agents
|h Elektronische Ressource
|b a review of the clinical effectiveness and guidelines
|
| 260 |
|
|
|a [Ottawa]
|b Canadian Agency for Drugs and Technologies in Health
|c 2016, 10 February 2016
|
| 300 |
|
|
|a 1 PDF file (11 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Monitoring, Intraoperative
|
| 653 |
|
|
|a Critical Care
|
| 653 |
|
|
|a Hypnotics and Sedatives / administration & dosage
|
| 653 |
|
|
|a Anesthesia Recovery Period
|
| 653 |
|
|
|a Neuromuscular Blocking Agents
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK350620
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of this report is to review the clinical efficacy and the evidence-based guidelines regarding neuromuscular monitoring for guiding treatment and therapy for patients in the intensive care unit receiving continuous paralytic or neuromuscular blocking agents
|